Skip to main content
Ipsen logo

Ipsen — Investor Relations & Filings

Ticker · IPN ISIN · FR0010259150 LEI · 549300M6SGDPB4Z94P11 PA Manufacturing
Open in API
Filings indexed 1,378 across all filing types
Latest filing 2017-11-14 Declaration of Voting R…
Country FR France
Listing PA IPN

About Ipsen

https://www.ipsen.com/

Ipsen is a global biopharmaceutical company focused on innovation and specialty care. The company develops and commercializes transformative medicines to address high unmet medical needs in three key therapeutic areas: oncology, rare diseases, and neuroscience. By leveraging its specialized expertise and strategic partnerships, Ipsen aims to accelerate the development of new therapies and improve health outcomes for patients worldwide. Its strategy is centered on advancing science with purpose to bring innovative treatments from research and development to the market.

Recent filings

Filing Released Lang Actions
Information relating to the total number of voting rights and shares making up the capital
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled 'Monthly information regarding the total number of voting rights and total number of shares of the Company' and explicitly references Article 223-16 of the AMF General Regulations. It provides a monthly update on the total number of shares and voting rights as of October 31, 2017. This type of periodic disclosure regarding share capital structure and voting rights does not fit neatly into the primary financial report categories (10-K, IR, ER). It is a specific regulatory disclosure. Among the provided codes, 'Declaration of Voting Results & Voting Rights Announcements' (DVA) is the most relevant category for official announcements concerning voting rights, even if this specific document is a monthly update rather than final results from a meeting. Given the specific nature of the content (voting rights count), DVA is the best fit over the general 'RNS' fallback.
2017-11-14 English
Quarterly financial report / Third quarter financial report
Earnings Release Classification · 98% confidence The document is a press release dated October 26, 2017, announcing Ipsen's sales results for the third quarter of 2017. It contains key financial highlights, pipeline updates, and detailed sales figures for the quarter and nine months ended. This format, focusing on periodic financial performance announcements outside of the comprehensive annual filing (10-K) or the full quarterly report (IR), strongly aligns with an Earnings Release (ER). It is an initial announcement of results, not a full report or a transcript of a call. Q3 2017
2017-10-26 English
Information financière trimestrielle / Information financière du troisième trimestre
Earnings Release Classification · 100% confidence The document is a press release from Ipsen announcing its financial results for the third quarter of 2017. It includes key highlights, financial tables (revenue by product and segment), and management commentary. It is a standard quarterly earnings release, which provides the initial announcement of financial performance for a specific period. It is not a full interim report (which would be a more comprehensive document) nor a report publication announcement (as it contains the actual financial data). Therefore, it is classified as an Earnings Release. Q3 2017
2017-10-26 French
Communicated under the obligation to provide permanent information / Other communications
Earnings Release Classification · 95% confidence The document is explicitly titled "PRESS RELEASE" and announces a significant clinical trial result (Phase 3 CELESTIAL trial met its primary endpoint for cabozantinib in advanced HCC). It provides key efficacy and safety data, context about the drug and the disease, and forward-looking statements regarding future regulatory filings (expected in H1 2018). This structure—a timely announcement of material, non-public information regarding clinical development and expected regulatory steps—is characteristic of an Earnings Release (ER) or a general press release announcing material news. Since it focuses on clinical trial success rather than comprehensive financial performance (like a 10-K or IR), and it is a direct announcement rather than a transcript (CT) or a presentation (IP), the most appropriate classification is Earnings Release (ER), as these releases often contain operational and clinical milestones alongside or instead of quarterly financials. Given the date (October 16, 2017) and the content, it functions as a material news announcement. FY 2017
2017-10-16 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Earnings Release Classification · 99% confidence The document is explicitly titled "PRESS RELEASE" and announces the positive results of a Phase 3 clinical study (CELESTIAL) for a drug (cabozantinib) in advanced hepatocellular carcinoma. It details the study design, efficacy results (OS), next regulatory steps (filing with EMA in H1 2018), and provides background on the disease and the drug. This format—a formal announcement of significant clinical trial data and immediate regulatory plans, issued as a press release—is characteristic of an Earnings Release (ER) or a general corporate/regulatory announcement. Since it is not a full financial report (10-K/IR), a transcript (CT), or a specific shareholder document (DEF 14A/DVA), and it is a primary announcement of material news, it best fits the 'Earnings Release' category, which often encompasses major operational/clinical milestones announced outside of scheduled earnings calls. Given the context of a major clinical trial success announcement, ER is the most appropriate fit among the provided options, as it communicates key performance/development news. FY 2017
2017-10-16 French
Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 98% confidence The document is titled "Information mensuelle relative au nombre total des droits de vote et d'actions composant le capital social" (Monthly information relating to the total number of voting rights and shares comprising the share capital). It explicitly references Article 223-16 of the AMF General Regulation (French financial regulator) and provides a table detailing the total number of shares and voting rights as of a specific date (September 30, 2017). This content directly relates to changes in the total share capital structure and voting rights, which aligns best with the 'Share Issue/Capital Change' category (SHA), as it reports on the composition of the capital.
2017-10-11 French

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.